Use of a rare disease patient registry in long-term post-authorisation drug studies

Dr. Diana Bilton joins The Lancet Respiratory Medicine to discuss how the use of rare disease patient registries helps with long term drug studies after drug authorisation. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv